Open Orphan Plc
ORPH.LN
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan is led by a management team with deep industry and financial experience.
Related content
Open Orphan surges thanks to first mover advantage in infectious disease
Open Orphan offers considerable first mover advantage in the fight against infectious diseases.
Open Orphan hails “transformation” as results deliver on promises
Open Orphan is making headlines as the Covid-19 pandemic highlights the importance of its work in the infectious diseases space.
Open Orphan branches out amid infectious disease gold rush
A new wave of research into malaria treatments has kicked off over the last 18 months. Which is great news for clinical research organisation Open...
Near-term profitability, spin outs, and challenge study contracts put Open Orphan on track for major valuation growth (ORPH)
After years of hard work, pharmaceutical services firm Open Orphan is reporting ongoing profitability.
Open Orphan expands human challenge trial capacity with new volunteer recruitment centres
Open Orphan and hVIVO’s human vaccine trial for Covid-19 begins
Open Orphan has a great start to 2021 with key 12-month contract renewal
Open Orphan wins vaccine contract extension and announces toxicology study completion
“We are scaling-up rapidly and at minimum expense” – Open Orphan’s Cathal Friel on the pharma services firm’s exciting plans for 2021 and beyond
Open Orphan and Codagenix receive MHRA approval for Covid vaccine challenge study
Open Orphan continues to convert deal pipeline with key Venn contracts
Open Orphan strengthens board with Elaine Sullivan hire
Open Orphan leads weighty Wellcome Trust bid to define human challenge drug standards
The Second-Gen Covid-19 Stocks Offering Explosive Opportunities
The Covid-19 pandemic will not end with a silver-bullet vaccine. We already know this, so wise traders are instead looking to the companies that do...
Open Orphan lands another £2.5m flu challenge study contract
